Information about medicines for patients in europe: To impede or to empower?

1Citations
Citations of this article
3Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Information about medicines in Europe does not really fulfil its potential. For patients, it is often very hard to understand and to apply information in a specific situation. For the pharmaceutical industry, it is hard to develop (writing-designing-testing) due to strict regulations. And for the Regulatory authorities, the current situation is hard to control and check. One of the main causes is that legal-, economic-, and health-criteria are simultaneously applied to information about medicines. However, these three criteria are fundamentally different, and have proved to be unbridgeable in the last 20 years. In order to provide patients with usable information, it seems essential to develop a legal system that is not based on standardization of processes and results, but instead is based on required performances in context. © Springer International Publishing Switzerland 2014.

Cite

CITATION STYLE

APA

Van Der Waarde, K. (2014). Information about medicines for patients in europe: To impede or to empower? In Lecture Notes in Computer Science (including subseries Lecture Notes in Artificial Intelligence and Lecture Notes in Bioinformatics) (Vol. 8519 LNCS, pp. 132–140). Springer Verlag. https://doi.org/10.1007/978-3-319-07635-5_14

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free